3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

BINDING ENERGETICS ANALYSIS SHOWS A UNIQUE RESPONSE OF TIPRANAVIR TO HIV-1 PROTEASE MUTATIONS ASSOCIATED WITH DRUG RESISTANCE

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePp0103

Muzammil S.¹, Kang L.-W.², Armstrong A.A.², Jakalian A.³, Bonneau P.R.³, Schmelmer V.⁴, Amzel L.M.², Freire E.^1
1 Department of Biology, Johns Hopkins University, Baltimore, MD, United States of America, ² Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, ³ Boehringer Ingelheim (Canada) Ltd. Research & Development, Laval, Québec, Canada, ⁴ Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States of America

BACKGROUND: Tipranavir (TPV) is a potent non-peptidic HIV-1 protease inhibitor currently in phase III clinical trials. We studied the inhibitory potency of TPV to the wild type protease and to commonly occurring drug-resistant mutations, including those associated with TPV resistance. Thermodynamics and crystallographic analysis elucidated the mechanisms by which TPV achieves its high affinity and eludes the deleterious effects of mutations.

METHODS: The inhibitory potency and binding energetics of TPV and other protease inhibitors were determined by enzyme inhibition and microcalorimetric measurements. The structures of TPV with wild type and mutant proteases were determined by x-ray crystallography.

RESULTS: TPV inhibits the wt protease with a Ki lower than 20 pM and exhibits extremely low loss of potency against known multi-drug resistant mutations. Mutations evaluated here included the active site mutants I50V and V82F/I84V; multidrug resistant L10I/L33I/M46I/I54V/L63I/V82A/I84V/L90M and M46I/A71V/G73S/V82A/I84V/L90M; and the TPV-selected mutant I13V/V32L/L33F/K45I/V82L/I84V. Against the TPV-selected mutant, only lopinavir had a 4-fold better response. Against all other mutants TPV averaged 30-fold lower Ki's than indinavir, amprenavir, lopinavir and atazanavir. Structurally, TPV establishes a very strong H-bond network with invariant regions, including catalytic Asp25 and backbone of Asp29, Asp30, Gly48 and Ile50. Uniquely, TPV H-bonds directly to Ile50. The binding of TPV to the wt protease is driven by a combination of favorable enthalpic (-0.7 kcal/mol) and entropic contributions (-13.9 kcal/mol). Against mutations, TPV either gains or loses very little enthalpic interactions.

CONCLUSIONS: Most inhibitors lose affinity against mutations due to combined enthalpy and entropy loses. Good response to mutations is achieved when enthalpy and entropy changes mutually compensate each other. Inhibitors that respond well usually compensate enthalpic loses with entropic gains. TPV is the first inhibitor that has shown the ability to maintain high inhibitory potency by either gaining or sustaining minimal loses in binding enthalpy.

Download PDF of this abstract.

050724
Basic | WePp0103 | Ernesto Freire
New Antiretroviral Targets And Compounds

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.